Terms: = Leukemia AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
11 results:
1. Molecular profiling of EBV associated diffuse large B-cell lymphoma.
Frontzek F; Staiger AM; Wullenkord R; Grau M; Zapukhlyak M; Kurz KS; Horn H; Erdmann T; Fend F; Richter J; Klapper W; Lenz P; Hailfinger S; Tasidou A; Trautmann M; Hartmann W; Rosenwald A; Quintanilla-Martinez L; Ott G; Anagnostopoulos I; Lenz G
Leukemia; 2023 Mar; 37(3):670-679. PubMed ID: 36604606
[TBL] [Abstract] [Full Text] [Related]
2. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
Tanaka N; Mori S; Kiyotani K; Ota Y; Gotoh O; Kusumoto S; Nakano N; Suehiro Y; Ito A; Choi I; Ohtsuka E; Hidaka M; Nosaka K; Yoshimitsu M; Imaizumi Y; Iida S; Utsunomiya A; Noda T; Nishikawa H; Ueda R; Ishida T
Haematologica; 2022 Oct; 107(10):2418-2431. PubMed ID: 35417939
[TBL] [Abstract] [Full Text] [Related]
3. Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome.
Di Raimondo C; Rubio-Gonzalez B; Palmer J; Weisenburger DD; Zain J; Wu X; Han Z; Rosen ST; Song JY; Querfeld C
Br J Dermatol; 2022 Aug; 187(2):234-243. PubMed ID: 35194801
[TBL] [Abstract] [Full Text] [Related]
4. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
Huemer F; Leisch M; Geisberger R; Melchardt T; Rinnerthaler G; Zaborsky N; Greil R
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325898
[TBL] [Abstract] [Full Text] [Related]
5. The role of TNF-α in chordoma progression and inflammatory pathways.
Gulluoglu S; Tuysuz EC; Sahin M; Yaltirik CK; Kuskucu A; Ozkan F; Dalan AB; Sahin F; Ture U; Bayrak OF
Cell Oncol (Dordr); 2019 Oct; 42(5):663-677. PubMed ID: 31175552
[TBL] [Abstract] [Full Text] [Related]
6. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/pd-l1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract] [Full Text] [Related]
7. Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.
Kawamoto K; Miyoshi H; Suzuki T; Kiyasu J; Yokoyama S; Sasaki Y; Sone H; Seto M; Takizawa J; Ohshima K
Hematol Oncol; 2018 Aug; 36(3):591-599. PubMed ID: 29602174
[TBL] [Abstract] [Full Text] [Related]
8. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.
Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D
Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224
[TBL] [Abstract] [Full Text] [Related]
9. [Expression and Significance of pd-l1, HSP90 and HSP90α in Serum of Patients with Acute leukemia].
Ma XJ; Zhang FH; Sun L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1384-1389. PubMed ID: 29070112
[TBL] [Abstract] [Full Text] [Related]
10. Markers and function of human NK cells in normal and pathological conditions.
Del Zotto G; Marcenaro E; Vacca P; Sivori S; Pende D; Della Chiesa M; Moretta F; Ingegnere T; Mingari MC; Moretta A; Moretta L
Cytometry B Clin Cytom; 2017 Mar; 92(2):100-114. PubMed ID: 28054442
[TBL] [Abstract] [Full Text] [Related]
11. Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.
Lipowska-Bhalla G; Fagnano E; Illidge TM; Cheadle EJ
Leuk Lymphoma; 2016; 57(6):1269-80. PubMed ID: 27050042
[TBL] [Abstract] [Full Text] [Related]
